Vir Biotechnology, Inc.
VIR· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -578.5%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- -2.1%
We record prices for the companies we cover; VIR is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 138.5M
- Revenue
- $68.6M
- Free cash flow
- -$396.6M
- Owner earnings
- -$445.7M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -699.2%
- Net
- -638.9%
- Free cash flow
- -578.5%
- Owner earnings
- -650.1%
- Stock pay
- 71.6%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -57.2%
- ROE, 5 yr avg
- -15.9%
Growth (CAGR)
- Revenue, 3 yr
- -65.1%
- Revenue, 5 yr
- -2.1%
- Revenue, 8 yr
- 49.8%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 8 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 8 yr
- –
Financial health · FY2025
- Cash and investments
- $460.9M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 3.1%
Financials: ten years from the 10-Ks
Revenue
$68.6M
+49.8% a year over 8 years
FY2017FY2025
Margins
Operating-699.2%Net-638.9%
FY2025
FY2017FY2025
Free cash flow and owner earnings
Free cash flow-$396.6MOwner earnings-$445.7M
FY2025
FY2017FY2025
Diluted shares
138.5M
+356.4% over 8 years, net dilution
FY2017FY2025
Every figure, year by year
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| The business | |||||||||
| Revenue | $2.7M | $10.7M | $8.1M | $76.4M | $1.1B | $1.6B | $86.2M | $74.2M | $68.6M |
| Revenue growth | – | 293.9% | -24.2% | 843.9% | 1334.4% | 47.5% | -94.7% | -13.9% | -7.6% |
| Gross margin | – | – | – | – | – | – | – | – | – |
| Operating margin | -3009.5% | -1112.6% | -2199.7% | -388.9% | 38.4% | 51.6% | -794.0% | -791.3% | -699.2% |
| Net income | -$69.9M | -$115.9M | -$174.7M | -$298.7M | $528.6M | $515.8M | -$615.1M | -$522.0M | -$438.0M |
| Net margin | -2579.5% | -1086.3% | -2159.0% | -391.1% | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| Diluted EPS | – | – | $-5.76 | $-2.51 | $3.96 | $3.83 | $-4.59 | $-3.83 | $-3.16 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – |
| Cash | |||||||||
| Operating cash flow | -$66.4M | -$94.1M | -$129.6M | -$190.9M | -$47.6M | $1.7B | -$778.8M | -$446.4M | -$391.8M |
| Capital expenditure | $2.7M | $8.2M | $8.9M | $6.5M | $21.8M | $68.0M | $21.6M | $7.3M | $4.8M |
| Free cash flow | -$69.1M | -$102.3M | -$138.6M | -$197.5M | -$69.4M | $1.6B | -$800.4M | -$453.7M | -$396.6M |
| Stock-based compensation | $4.8M | $5.1M | $8.7M | $27.6M | $83.8M | $102.1M | $111.3M | $78.5M | $49.1M |
| Owner earnings? | -$73.9M | -$107.3M | -$147.3M | -$225.1M | -$153.2M | $1.5B | -$911.7M | -$532.1M | -$445.7M |
| Free cash flow per share | – | – | $-4.57 | $-1.66 | $-0.52 | $11.83 | $-5.97 | $-3.33 | $-2.86 |
| Capital allocation | |||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – |
| Diluted shares | – | – | 30.3M | 119.2M | 133.4M | 134.8M | 134.1M | 136.2M | 138.5M |
| Share count change? | – | – | – | 292.6% | 12.0% | 1.0% | -0.5% | 1.6% | 1.7% |
| Balance sheet | |||||||||
| Cash and equivalents | $187.9M | $47.6M | $109.3M | $436.6M | $347.8M | $848.6M | $241.6M | $222.9M | $232.2M |
| Short-term investments | – | $50.8M | $274.1M | $300.3M | $217.2M | $1.5B | $1.3B | $678.1M | $228.8M |
| Total debt | – | – | – | – | – | – | – | – | – |
| Net debt | – | – | – | – | – | – | – | – | – |
| Shareholders' equity | -$68.9M | -$179.2M | $423.9M | $716.9M | $1.4B | $2.1B | $1.6B | $1.2B | $765.3M |
Latest filings
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Earnings release |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Earnings release |
| 2026-04-16 | DEF 14A | Proxy statement |
| 2026-02-23 | 10-K | Annual report |
| 2026-02-23 | 8-K | Earnings release |
| 2026-01-12 | 8-K | Earnings release |
| 2025-11-05 | 10-Q | Quarterly report |
| 2025-11-05 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
